Corcept Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Corcept Therapeutics Inc CORT.OQ reported quarterly adjusted earnings of 20 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 41 cents. The mean expectation of six analysts for the quarter was for earnings of 14 cents per share. Wall Street expected results to range from 3 cents to 29 cents per share.

• Revenue rose 13.7% to $207.64 million from a year ago; analysts expected $218.53 million.

• Corcept Therapeutics Inc's reported EPS for the quarter was 16 cents​.

• The company reported quarterly net income of $19.67 million.

• Corcept Therapeutics Inc shares had risen by 1.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 122.2% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Corcept Therapeutics Inc is $100.00, about 64.7% above its last closing price of $35.34

This summary was machine generated from LSEG data February 24 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)